Related Experiment Video

Updated: Dec 24, 2025

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.5K

Outcome measures in pediatric polypharmacy research: a scoping review

Negar Golchin1, Hannah Johnson2, Paul M Bakaki2

  • 1School of Pharmacy, University of Washington, Seattle, Washington, USA.

Drugs & Therapy Perspectives : for Rational Drug Selection and Use
|April 8, 2020
PubMed

Insights

This scoping review analyzed pediatric polypharmacy research, finding most studies focus on prevalence, prognosis, and adverse drug reactions. Researchers highlight the harms of polypharmacy, urging careful consideration of benefits versus risks.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Health Outcomes Research

Background:

  • Pediatric polypharmacy research has employed various interpretation methods.
  • This study represents the first scoping review to explore outcome measures in pediatric polypharmacy research.

Purpose of the Study:

  • To systematically describe the outcome measures assessed within the existing body of pediatric polypharmacy research.

Main Methods:

  • A comprehensive search of multiple electronic databases was conducted in July 2017.
  • Data extraction focused on study characteristics and outcome measures, with synthesis of reported harms and benefits.
  • Included studies were analyzed for prevalence, prognosis, and adverse drug reaction outcomes.

Main Results:

  • Out of 363 analyzed studies, polypharmacy prevalence was the most frequent outcome (31.4%), followed by prognosis (25.6%) and adverse drug reactions (16.5%).
  • A significant majority of studies (73.0%) reported harms, including adverse drug reactions, side effects, and drug-drug interactions.
  • Benefits were reported in 22.9% of studies, often related to efficacy, complex disease treatment, or treatment augmentation.

Conclusions:

  • The majority of pediatric polypharmacy studies concentrate on prevalence, prognosis, and adverse drug reaction outcomes.
  • Findings underscore the significant harms associated with pediatric polypharmacy.
  • Clinicians must meticulously balance the potential benefits against the harms when prescribing multiple medications for pediatric patients.
Abstract

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

6.2K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
150
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
176
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
134
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
97
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
178